Upvote
Downvote
Scientist
Share Job
- Suggest Revision
Full-time
- Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.
- The name Acrivon (derived from Greek for "accurate") embodies how our OncoSignature tests link the patient's active tumor-driving mechanisms with the drug's mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations.
- The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment.
- The Scientist will be a key member of Acrivon Therapeutics' Drug Discovery Team and will be supporting its in vitro pharmacology, mechanism-of-action studies, and biomarker identification efforts.
- Perform cell line engineering, assay development, and large cell line panel screens.
Active Job
Updated 1 month agoSimilar Job
Relevance
Active